Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: A phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F07%3A00050902" target="_blank" >RIV/00216224:14110/07:00050902 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.clinthera.2007.08.002" target="_blank" >http://dx.doi.org/10.1016/j.clinthera.2007.08.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clinthera.2007.08.002" target="_blank" >10.1016/j.clinthera.2007.08.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: A phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration

Popis výsledku v původním jazyce

The aim of this study was to assess the efficacy and tolerability of garenoxacin in adults with acute bacterial maxillary sinusitis undergoing a pretreatment diagnostic sinus aspirate. Garenoxacin is a des-F(6)-quinolone with in vitro activity against key respiratory pathogens, including Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. This Phase II, multicenter, noncomparative, open-label study was conducted at 30 centers in the United States, Mexico, Argentina, and Europe. Conclusion: In this population of patients with signs and symptoms of acute maxillary sinusitis, oral garenoxacin 400 mg QD for 5 or 10 days eradicated 94 % of bacterial pathogens associated with acute bacterial sinusitis in this population and appeared to be well tolerated in adults.

Název v anglickém jazyce

Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: A phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration

Popis výsledku anglicky

The aim of this study was to assess the efficacy and tolerability of garenoxacin in adults with acute bacterial maxillary sinusitis undergoing a pretreatment diagnostic sinus aspirate. Garenoxacin is a des-F(6)-quinolone with in vitro activity against key respiratory pathogens, including Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. This Phase II, multicenter, noncomparative, open-label study was conducted at 30 centers in the United States, Mexico, Argentina, and Europe. Conclusion: In this population of patients with signs and symptoms of acute maxillary sinusitis, oral garenoxacin 400 mg QD for 5 or 10 days eradicated 94 % of bacterial pathogens associated with acute bacterial sinusitis in this population and appeared to be well tolerated in adults.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FF - ORL, oftalmologie, stomatologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Therapeutics

ISSN

0149-2918

e-ISSN

—

Svazek periodika

29

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

1632-1644

Kód UT WoS článku

000249682900009

EID výsledku v databázi Scopus

—